Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Cosentyx Drug Market Size Shifted, And What Is the Outlook Through 2034?
The market size of the cosentyx drug has exhibited significant growth over the past few years. It is predicted to expand from $5,195.11 million in 2024 to $5,683.20 million in 2025, with a compound annual growth rate (CAGR) of 9.4%. The growth seen in the historic time frame can be attributed to various factors like FDA approval and early market entry, clinical efficacy and safety profile, a shift towards biologics, real-world data, long-term benefits, and global regulatory approvals.
How Much Will the Cosentyx Drug Market Be Worth in 2029?
We anticipate a robust surge in the market size of the Cosentyx drug in the ensuing years, with projections estimating it will reach up to $8,030.80 million by 2029, growing at a compound annual growth rate (CAGR) of 9.0%. Multiple factors are believed to contribute to this growth over the forecast period including a rising incidence of autoimmune diseases, the broadening of approved indications, forward strides in biologic treatments, favorable reimbursement schemes, and compelling clinical outcomes. Notable forecast period trends include broader application scopes for autoimmune diseases, a pivot towards personalized medicine, the continued prevalence of subcutaneous administration, and heightened R&D activity in new therapeutic areas.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp
Which is the Largest Company in the Cosentyx Drug Market?
Major companies operating in the cosentyx drug market include Novartis AG
What Are the Main Market Drivers in the Cosentyx Drug Industry?
The surge in autoimmune diseases is predicted to spark the growth of the cosentyx market in the future. Autoimmune diseases are conditions in which the immune system erroneously attacks the body’s normal cells and tissues. The surge in autoimmune diseases is due to genetic susceptibility, environmental elements like infections and pollutants, and lifestyle alterations, including heightened stress and changes in diet. Cosentyx (secukinumab) aids in the management of autoimmune diseases by focusing on and blocking interleukin-17A, an essential cytokine in the inflammation process. This reduces symptoms, enhances the quality of life, and efficiently treats conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, in July 2023, data from Public Health Scotland revealed that the newly diagnosed cases of multiple sclerosis (MS) had risen to 87.2%, a jump from 85.7%, with 491 new cases, taking the count to 6,359 in 2022. Therefore, the surge in autoimmune diseases is fuelling the cosentyx market. The growing healthcare expenditure is also predicted to fuel the cosentyx market expansion. Healthcare expenditure refers to the overall spending on health-related products and services, from personal healthcare to preventive services and public health initiatives, all aiming to improve health results over a fixed period. The increasing healthcare expenditure is a result of aging populations, chronic illnesses, sophisticated medical technology, high drug costs, ineffective payment models, and a rising demand for services. The expenditure on Cosentyx is primarily aimed at managing moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, and improving patient outcomes through targeted biologic therapy. For instance, a report from Office For National Statistics in May 2024 stated that the total healthcare expenditure had increased by 5.6% in nominal terms from 2022 to 2023, contrasting with a growth rate of 0.9% in 2022. Moreover, the total spending on long-term health and social care grew by 2.8% in real terms in 2022. Thus, the increase in healthcare expenditure is bolstering the cosentyx market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19891&type=smp
How Is the Cosentyx Drug Market Segments Structured?
The cosentyx drugmarket covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa; Psoriatic arthritis; Ankylosing spondylitis; Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection; Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
What Strategic Trends Are Transforming the Cosentyx Drug Market?
A key trend paving the wave for the market of Cosentyx drug focuses on progressing towards more advanced therapies like the biological treatment options to cater to the unmet medical requirements, improve the treatment’s efficiency and provide targeted therapies for the management of chronic autoimmune conditions. This in turn fortifies their market standing and caters to the growing needs of the patient population. Biological treatments are sophisticated therapies obtained from living organisms or their cells that target specific components of the immune system, such as interleukin-17A, to regulate inflammatory responses and effectively treating autoimmune conditions like psoriasis, psoriatic arthritis and ankylosing spondylitis. To illustrate, Novartis AG, a pharmaceutical company based in Switzerland, secured FDA approval for Cosentyx (secukinumab) in October 2023 being the first fresh biologic treatment option for moderate to severe hidradenitis suppurativa (HS) almost in a decade. This approval signifies a marked progress in regards to treatment outlook for HS which is a chronic and often severe skin condition characterized by painful lumps leading to scarring and psychological distress.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report
Which Global Regions Offer the Highest Growth in the Cosentyx Drug Market?
North America was the largest region in the cosentyx drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19891
This Report Delivers Insight On:
1. How big is the cosentyx drug market, and how is it changing globally?
2. Who are the major companies in the cosentyx drug market, and how are they performing?
3. What are the key opportunities and risks in the cosentyx drug market right now?
4. Which products or customer segments are growing the most in the cosentyx drug market?
5. What factors are helping or slowing down the growth of the cosentyx drug market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model